Peptides that modulate immune function span two distinct axes: the adaptive immune system — T-cell maturation, dendritic-cell priming, antigen presentation — and the innate immune system — antimicrobial defense, pattern recognition, and rapid first-response signaling.
Immune-modulating peptides divide cleanly by mechanism. Understanding which axis a compound acts on is the first step in interpreting research findings.
Axis 1
The adaptive system learns and remembers. Peptides like thymosin α1 act on dendritic cells and T-cell progenitors, promoting differentiation from naïve to effector cells and upregulating MHC class I — the machinery that presents antigens to cytotoxic T lymphocytes.
Axis 2
The innate system responds fast and non-specifically. Antimicrobial peptides like LL-37 disrupt pathogen membranes directly, modulate TLR signaling to calibrate the inflammatory response, and recruit immune cells to sites of infection or injury.
Mechanism, evidence level, and key research context for each compound in this cluster.
T-cell maturation, dendritic-cell activation, MHC I upregulation
Chain
28 aa
Half-life
~2 hours (sc)
Receptor
TLR2 / TLR9 / DC surface
FDA status
Not approved (US)
Actin sequestration, tissue remodeling, anti-inflammatory via Ac-SDKP
Chain
43 aa
Half-life
Unknown (endogenous)
Receptor
G-actin (sequestration), ILK
FDA status
Not approved
Antimicrobial membrane disruption, TLR modulation, wound healing
Chain
37 aa
Half-life
Minutes (plasma)
Receptor
Bacterial membranes, TLR4 modulation, FPRL1
FDA status
Not approved
Immune–Repair Interface
Despite sharing the “thymosin” name, thymosin β4 (Tβ4) is mechanistically unrelated to thymosin α1. Where thymosin α1 acts on immune-cell differentiation via TLR signaling, Tβ4 works by sequestering G-actin monomers — regulating cytoskeletal dynamics, wound healing, and angiogenesis. Its anti-inflammatory effects are largely mediated by the Ac-SDKP fragment, which inhibits NF-κB activation.
G-actin sequestration
Binds monomeric actin (Kd ~0.5 μM), regulating filament assembly and cell motility
Ac-SDKP fragment
A tetrapeptide cleaved from the N-terminus; inhibits NF-κB and fibrosis markers
TB-500 synthetic fragment
Residues 17–23 (LKKTETQ) — retains actin-binding activity, easier to synthesize
Evidence levels across the immune cluster — matched to the 6-level evidence hierarchy.
| Compound | Axis | Highest evidence | Human trials | Approval status |
|---|---|---|---|---|
| Thymosin α1 | Adaptive | Phase 3 / Approved (non-US) | Yes — Phase 3 RCTs (hepatitis, melanoma) | Zadaxin (~35 countries); Not FDA-approved |
| LL-37 | Innate | Preclinical / Phase 1 | Limited — Phase 1 wound/topical studies | Not approved anywhere |
| Thymosin β4 | Repair bridge | Phase 1/2 (wound healing) | Phase 1/2 wound-healing trials | Not approved |
| TB-500 (Tβ4 fragment) | Repair bridge | Preclinical | None | Not approved; WADA prohibited |
Thymosin α1 is a 28-amino-acid peptide originally isolated from thymic tissue. In research models it activates dendritic cells, promotes T-cell maturation, and upregulates MHC class I expression. It is approved under the name Zadaxin in several countries for hepatitis B, hepatitis C, and adjunctive use in certain cancers, but is not FDA-approved in the United States.
No. Thymosin α1 (brand name Zadaxin) is approved in approximately 35 countries for specific indications but has not received FDA approval. It holds orphan-drug designation in the US for certain applications. Any use outside approved jurisdictions is investigational.
LL-37 is a 37-amino-acid cathelicidin — the only member of that antimicrobial peptide family identified in humans. It disrupts bacterial membranes, modulates Toll-like receptor (TLR) signaling, and promotes wound healing. Evidence is largely preclinical; a small number of Phase 1/2 studies have examined topical and intravenous formulations.
Despite sharing the "thymosin" name, thymosin α1 and thymosin β4 are structurally and functionally distinct. Thymosin α1 is a thymic peptide that primarily modulates adaptive immunity (T-cell activation, dendritic-cell priming). Thymosin β4 sequesters G-actin monomers, drives tissue remodeling, and has anti-inflammatory properties via its Ac-SDKP fragment — it belongs to the healing and repair axis, not the thymic immunology axis.
TB-500 is a synthetic peptide fragment corresponding to amino acids 17–23 of thymosin β4 (sequence: LKKTETQ). This fragment retains the actin-binding and tissue-repair activity associated with full-length Tβ4, while being shorter and easier to synthesize. It is a research chemical with no approved clinical use.
Evidence varies by compound. Thymosin α1 has Phase 3 trial data and multi-country approval for specific indications. LL-37 is primarily preclinical with limited Phase 1/2 data. Thymosin β4 has Phase 1/2 wound-healing trial data. None are FDA-approved; all require further validation before clinical conclusions can be drawn from research findings.
No. The peptides covered here are immunomodulatory, not broadly immunosuppressive. Thymosin α1 generally upregulates immune readiness (useful in immunocompromised states); LL-37 amplifies innate antimicrobial responses. Immunosuppressants reduce immune activity (e.g., for autoimmune disease or transplant rejection) — the mechanism is opposite.
Other Research Clusters